Matches in Wikidata for { <http://www.wikidata.org/entity/Q66034303> ?p ?o ?g. }
Showing items 1 to 41 of
41
with 100 items per page.
- Q66034303 description "clinical trial" @default.
- Q66034303 description "ensayu clínicu" @default.
- Q66034303 description "klinisch onderzoek" @default.
- Q66034303 description "клінічне випробування" @default.
- Q66034303 name "Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis" @default.
- Q66034303 name "Zenapax" @default.
- Q66034303 type Item @default.
- Q66034303 label "Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis" @default.
- Q66034303 label "Zenapax" @default.
- Q66034303 prefLabel "Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis" @default.
- Q66034303 prefLabel "Zenapax" @default.
- Q66034303 P1050 Q66034303-59F2B75C-8525-47AA-BCA5-47935EF12DF2 @default.
- Q66034303 P1050 Q66034303-FA2EC56C-EFAE-40C2-990A-D7E916472C60 @default.
- Q66034303 P1132 Q66034303-7125441C-E84E-4631-A85F-368FD7CFF239 @default.
- Q66034303 P1476 Q66034303-ECF75F36-C7A1-46EA-AC4A-578D1F16B96D @default.
- Q66034303 P17 Q66034303-E45202F3-A5EC-4AA5-9B47-2A96921CEDB9 @default.
- Q66034303 P2899 Q66034303-13D6FFB0-78C0-4F3D-B3DF-E3B7E181B37E @default.
- Q66034303 P3098 Q66034303-45CBAB9C-CFED-468B-A158-46BD275A69FF @default.
- Q66034303 P31 Q66034303-D2A7CFB7-2ABD-4632-9F0D-062547462252 @default.
- Q66034303 P4135 Q66034303-8D48B1AD-C508-47D5-89E6-3F2C1E3B3BC6 @default.
- Q66034303 P580 Q66034303-601039D2-1004-4289-847B-B2BB31B7D9A8 @default.
- Q66034303 P582 Q66034303-7352F883-467B-4199-AD52-1CA230A58079 @default.
- Q66034303 P6099 Q66034303-E16F8FB9-5927-4CA9-B3BC-43996AF83F8D @default.
- Q66034303 P6153 Q66034303-EF5541F7-F6B4-4C0D-B759-562BDD26464C @default.
- Q66034303 P8363 Q66034303-1A316AAF-2728-4705-9E7D-71F85B4FDBC7 @default.
- Q66034303 P921 Q66034303-52F0199F-082F-4832-99A5-D70D484F09A9 @default.
- Q66034303 P1050 Q140067 @default.
- Q66034303 P1050 Q8277 @default.
- Q66034303 P1132 "+16" @default.
- Q66034303 P1476 "Zenapax (Daclizumab) Admin to Pts With Multiple Sclerosis (ZAP MS): Effect of Intravenously Admin Humanized Monoclonal Antibody Against the Interleukin-2 Receptor Alpha Subunit (Daclizumab) on Inflammatory Activity in the Central Nervous System" @default.
- Q66034303 P17 Q30 @default.
- Q66034303 P2899 "+18" @default.
- Q66034303 P3098 "NCT00071838" @default.
- Q66034303 P31 Q30612 @default.
- Q66034303 P4135 "+65" @default.
- Q66034303 P580 "2003-10-30T00:00:00Z" @default.
- Q66034303 P582 "2007-10-04T00:00:00Z" @default.
- Q66034303 P6099 Q42824440 @default.
- Q66034303 P6153 Q390551 @default.
- Q66034303 P8363 Q78089383 @default.
- Q66034303 P921 Q1186703 @default.